Amgen To Present At The Morgan Stanley Global Healthcare Conference
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/21/2026
- Wall Street indexes fall, with Iran and earnings season in focus
- Oil settles 1% higher as hopes of renewed US-Iran negotiations offset Houthi threat
- Selloff of U.S. memory stocks creates a compelling entry point: analyst
- Why Moonshot AI's Kimi K3 is actually bullish for memory stocks
- AMC Entertainment soars on record quarterly results
- U.S. to impose 50% tariff on most Canadian goods, including USMCA
- NVIDIA reports 9.3% passive stake in Nebius
- Wall Street indexes fall, with Iran and earnings season in focus
- Cantor Fitzgerald Starts Trulieve Cannabis (TRLV) at Overweight, 'Purpose-Built for a New Cannabis Regulatory Framework'
- Selloff of U.S. memory stocks creates a compelling entry point: analyst
Baird 'Incrementally Positive' on Amgen's (AMGN) Initial AMG 420 results
September 10, 2018 12:01 PM EDTBaird analyst Brian Skorney is incrementally positive on Amgen's (NASDAQ: AMGN) initial AMG 420 results.
"We think the very first clinical results for Amgen's anti-BCMA BiTE look very promising and competitive with those of the CART approach (CELG/BLUE/JNJ)," Skorney said. "We... More
